GlassScriptPhysician profile
Hazar Michael
NPI 1144392242
$754.77
in general payments reported to CMS, 2019-2025
10 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50.61 · 2021: $11.90 · 2022: $136 · 2023: $118 · 2024: $243 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $536 · Education: $19.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.27 |
| Education | $19.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $258.06 | 2022-2024 | |
| Gilead Sciences, INC. | $188.62 | 2019-2025 | Livdelzi |
| Celgene Corporation | $71.19 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.30 | 2023-2024 | Xifaxan |
| Olympus America INC. | $36.46 | 2019-2023 | Evis Exera Lll Colonovideoscope |
| Ferring Pharmaceuticals INC. | $32.85 | 2023 | Rebyota |
| Micro-Tech Endoscopy USA, INC. | $32.60 | 2023-2024 | Dat Device, Lesion Hunter |
| Pfizer INC. | $30.35 | 2019-2024 | |
| Genzyme Corporation | $21.24 | 2025 | |
| Lilly USA, LLC | $18.10 | 2024 | Omvoh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hazar Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.